Upload
PPT-Figure Figure. Ebola virus inactivation results as tested in BALB/c mouse model. A) Survival

PPT-Figure Figure. Ebola virus inactivation results as tested in BALB/c mouse model. A) Survival

Author : tremblay | Published Date : 2024-03-13

Haddock E Feldmann F Feldmann H Effective Chemical Inactivation of Ebola Virus Emerg Infect Dis 201622712921294 httpsdoiorg103201eid2207160233

µl buffer rlt groups buffer groups rlt avl inactivation tested sample ebola treatment qiagen cells virus feldmann

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure Figure. Ebola virus inactivation ..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure Figure. Ebola virus inactivation results as tested in BALB/c mouse model. A) Survival: Transcript

Haddock E Feldmann F Feldmann H Effective Chemical Inactivation of Ebola Virus Emerg Infect Dis 201622712921294 httpsdoiorg103201eid2207160233. AGENTS. . THAT. . INACTIVATE. . VIRUS INFECTIVITY. . 1. . Physical. . agents. . . 1.a. . Temperature. All. . infective. . viruses. . lose. . infectivity. . over. . time,. . Ovary – Cyst 1 Ovary – Cyst cysts increase with age, and the walls become so thin that identifying features are lost. The pathogenesis of ovarian cysts is often unknown; however, in mice s Selim AA, Erfan AM, Hagag N, Zanaty A, Samir A, Samy M, et al. Highly Pathogenic Avian Influenza Virus (H5N8) Clade 2.3.4.4 Infection in Migratory Birds, Egypt. Emerg Infect Dis. 2017;23(6):1048-1051. https://doi.org/10.3201/eid2306.162056. Fischer RJ, Judson SD, Miazgowicz K, Bushmaker T, Munster VJ. Ebola Virus Persistence in Semen Ex Vivo. Emerg Infect Dis. 2016;22(2):289-291. https://doi.org/10.3201/eid2202.151278. Griffin I, Martin SW, Fischer M, Chambers TV, Kosoy O, Falise A, et al. Zika Virus IgM Detection and Neutralizing Antibody Profiles 12–19 Months after Illness Onset. Emerg Infect Dis. 2019;25(2):299-303. https://doi.org/10.3201/eid2502.181286. Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, et al. Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection. Emerg Infect Dis. 2004;10(1):109-116. https://doi.org/10.3201/eid1001.020714. Wawina-Bokalanga T, Vanmechelen B, Lhermitte V, Martí-Carreras J, Vergote V, Koundouno F, et al. Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes. Emerg Infect Dis. 2021;27(1):76-84. https://doi.org/10.3201/eid2701.202177. Torrez-Martinez N, Bharadwaj M, Goade D, Delury J, Moran P, Hicks B, et al. Bayou Virus-Associated Hantavirus Pulmonary Syndrome in Eastern Texas: Identification of the Rice Rat, Oryzomys palustris, as Reservoir Host. Emerg Infect Dis. 1998;4(1):105-111. https://doi.org/10.3201/eid0401.980115. Shoemaker T, MacNeil A, Balinandi S, Campbell S, Wamala J, McMullan LK, et al. Reemerging Sudan Ebola Virus Disease in Uganda, 2011. Emerg Infect Dis. 2012;18(9):1480-1483. https://doi.org/10.3201/eid1809.111536. de Vries RD, De Gruyter H, Bestebroer TM, Pronk M, Fouchier R, Osterhaus A, et al. Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine. Emerg Infect Dis. 2015;21(6):1086-1088. https://doi.org/10.3201/eid2106.150021. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Biomarker Correlates of Survival in Pediatric Patients with Ebola Virus Disease. Emerg Infect Dis. 2014;20(10):1683-1690. https://doi.org/10.3201/eid2010.140430. Chancellor JR, Padmanabhan SP, Greenough TC, Sacra R, Ellison RT, Madoff LC, et al. Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease. Emerg Infect Dis. 2016;22(2):295-297. https://doi.org/10.3201/eid2202.151416. Kirschner DE, Webb G. Resistance, Remission, and Qualitative Differences in HIV Chemotherapy. Emerg Infect Dis. 1997;3(3):273-283. https://doi.org/10.3201/eid0303.970303. Buehring G, Shen H, Jensen HM, Choi K, Sun D, Nuovo G. Bovine Leukemia Virus DNA in Human Breast Tissue. Emerg Infect Dis. 2014;20(5):772-782. https://doi.org/10.3201/eid2005.131298.

Download Document

Here is the link to download the presentation.
"Figure Figure. Ebola virus inactivation results as tested in BALB/c mouse model. A) Survival"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents

Figure Legend Figure 1 Ovary Cystin a female B6C3F1N mouse from a

Figure Legend Figure 1 Ovary Cystin a female B6C3F1N mouse from a
Figure Figure. Structural and phylogenetic modeling of highly pathogenic avian influenza

Figure Figure. Structural and phylogenetic modeling of highly pathogenic avian influenza
Figure 1 Figure 1. A) Standard curves of Ebola virus spiked into 3 matrices: semen, blood,

Figure 1 Figure 1. A) Standard curves of Ebola virus spiked into 3 matrices: semen, blood,
Figure Figure. Zika virus IgM results for 62 participants in Miami–Dade County, Florida,

Figure Figure. Zika virus IgM results for 62 participants in Miami–Dade County, Florida,
Figure Figure. Kaplan-Meier survival curves showing disease-free survival for

Figure Figure. Kaplan-Meier survival curves showing disease-free survival for
Figure 2 Figure 2. HLA haplotypes identified among the control group, Ebola survivors,

Figure 2 Figure 2. HLA haplotypes identified among the control group, Ebola survivors,
Figure 3 Figure 3. Western blot assay for detecting IgG antibodies in patient

Figure 3 Figure 3. Western blot assay for detecting IgG antibodies in patient
Figure 1 Figure 1. . . Sudan Ebola virus in Uganda, 2011. A) Geographic locations of Nakisimata

Figure 1 Figure 1. . . Sudan Ebola virus in Uganda, 2011. A) Geographic locations of Nakisimata
Figure Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia

Figure Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia
Figure 1 Figure 1. Viral loads for Ebola virus disease patients infected with Sudan virus

Figure 1 Figure 1. Viral loads for Ebola virus disease patients infected with Sudan virus
Figure 1 Figure 1. Slit lamp examination of the left eye of a physician from the United

Figure 1 Figure 1. Slit lamp examination of the left eye of a physician from the United
Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient
Figure 4 Figure 4. Test results showing lack of cross-reactivity of bovine leukemia virus

Figure 4 Figure 4. Test results showing lack of cross-reactivity of bovine leukemia virus